ALNY vs. RGEN: Alnylam Pharmaceuticals vs. Repligen Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while RGEN is classified in Life Sciences Tools & Services.
| Profile Item | ALNY | RGEN |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | Repligen Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 20.89 billion USD | 11.09 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2004 | April 29, 1986 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | RGEN |
|---|---|---|
| Total Return (1Y) | -64.57% | 23.28% |
| Total Return (3Y, Annualized) | -1.58% | 6.20% |
| Total Return (5Y, Annualized) | -3.13% | -8.41% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | RGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 46.73% |
| Beta (5Y) | 0.45 | 1.11 |
| Max Drawdown (5Y) | -68.25% | -64.67% |
| Avg. Volume (3M) | 1.90M | 1.18M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | RGEN |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 0.41 |
| Sortino Ratio (1Y) | -1.45 | 0.60 |
Profitability
ROE (TTM)
Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 138.07%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.57%
- Max
- 109.18%
- Q3
- 6.23%
- RGEN
- -0.57%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Alnylam Pharmaceuticals (ALNY) reports 52.85%, ranking against industry peers normally.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-1.47%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- RGEN
- -1.47%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Alnylam Pharmaceuticals (ALNY) at 23.72% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.19%
- Max
- 83.12%
- Q3
- 14.77%
- RGEN
- 6.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | RGEN |
|---|---|---|
| ROE (TTM) | 138.07% | -0.57% |
| ROA (TTM) | 9.51% | 1.40% |
| Net Margin (TTM) | 52.85% | -1.47% |
| Operating Margin (TTM) | 23.72% | 6.19% |
| Gross Margin (TTM) | 77.28% | 53.77% |
Growth
Revenue Growth
Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Repligen (RGEN) at 16.36% is closer to the peer norm — faster top-line expansion for ALNY.
EPS Growth
Neither Alnylam Pharmaceuticals (ALNY) nor Repligen (RGEN) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ALNY | RGEN |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 16.36% |
| Revenue Growth (3Y CAGR) | 52.98% | -2.70% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -35.73% |
Financial Strength
Current Ratio (MRQ)
Both Alnylam Pharmaceuticals (ALNY) at 2.48 and Repligen (RGEN) at 9.88 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88
- Max
- 25.13
- Q3
- 12.13
- RGEN
- 9.88
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Repligen (RGEN) at 0.33 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.33
- Max
- 1.42
- Q3
- 0.65
- RGEN
- 0.33
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ALNY | RGEN |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 9.88 |
| Debt / Equity (MRQ) | 0.83 | 0.33 |
| Net Debt / EBITDA | -0.57 | -1.19 |
Dividends
Dividend Yield (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | RGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Alnylam Pharmaceuticals (ALNY) trades at 7.88 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RGEN
- --
P/S Ratio (TTM)
On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Repligen (RGEN) at 13.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.77
- Max
- 58.18
- Q3
- 25.77
- RGEN
- 13.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Alnylam Pharmaceuticals (ALNY) at 5.79 and Repligen (RGEN) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- RGEN
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | RGEN |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | -- |
| P/S Ratio (TTM) | 4.17 | 13.77 |
| P/B Ratio (MRQ) | 5.79 | 4.70 |
| Free Cash Flow Yield (TTM) | 1.57% | 1.01% |